Rituximab Terminated Phase 2 / 3 Trials for Recurrent Grade 3 Follicular Lymphoma / Follicular Lymphoma (FL) / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 1 Follicular Lymphoma Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2 / 3
clinicaltrials.gov IdentifierTitleDrugs
NCT01313611BRIEF Bendamustine and Rituximab In Elderly Follicular
NCT00850499Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab
NCT00901927Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma
NCT00510887Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma
NCT00308087Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma
NCT01902862An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma